Ireland - English - HPRA (Health Products Regulatory Authority)

teva pharma b.v. - latanoprost - eye drops, solution - 50 microgram(s)/millilitre - prostaglandin analogues1); latanoprost

United States - English - NLM (National Library of Medicine)

pfizer laboratories div pfizer inc - latanoprost (unii: 6z5b6hvf6o) (latanoprost - unii:6z5b6hvf6o) - latanoprost 50 ug in 1 ml - xalatan is indicated for the reduction of elevated intraocular pressure (iop) in patients with open-angle glaucoma or ocular hypertension. known hypersensitivity to latanoprost, benzalkonium chloride, or any other ingredients in this product. there are no adequate and well-controlled studies of xalatan administration in pregnant women.to inform drug-associated risks. in animal reproduction studies, intravenous (iv) administration of latanoprost to pregnant rabbits and rats throughout the period of organogenesis produced malformations, embryofetal lethality and spontaneous abortion at clinically relevant doses [see data] . the background risk of major birth defects and miscarriage for the indicated population is unknown. however, the background risk in the u.s. general population of major birth defects is 2 to 4%, and of miscarriage is 15 to 20% of clinically recognized pregnancies. embryofetal studies were conducted in pregnant rabbits administered latanoprost daily by iv injection on gestation days 6 through

United States - English - NLM (National Library of Medicine)

dispensing solutions, inc. - latanoprost (unii: 6z5b6hvf6o) (latanoprost - unii:6z5b6hvf6o) - latanoprost 50 ug in 1 ml - xalatan sterile ophthalmic solution is indicated for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension. known hypersensitivity to latanoprost, benzalkonium chloride or any other ingredients in this product.

Australia - English - Department of Health (Therapeutic Goods Administration)

aspen pharmacare australia pty ltd - latanoprost, quantity: 50 microgram/ml - eye drops, solution - excipient ingredients: dibasic sodium phosphate; benzalkonium chloride; sodium chloride; water for injections; monobasic sodium phosphate monohydrate - reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension.

Canada - English - Health Canada

mint pharmaceuticals inc - timolol (timolol maleate); latanoprost - solution - 5mg; 50mcg - timolol (timolol maleate) 5mg; latanoprost 50mcg - beta-adrenergic agents

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - latanoprost, quantity: 50 microgram/ml; timolol maleate, quantity: 5 mg/ml - eye drops, solution - excipient ingredients: benzalkonium chloride; monobasic sodium phosphate monohydrate; water for injections; sodium hydroxide; dibasic sodium phosphate; hydrochloric acid; sodium chloride - reduction of elevated intraocular pressure in patients with open-angle glaucoma and ocular hypertension who are insufficiently responsive to beta-blockers, prostaglandins or other intraocular pressure lowering medications. latanoprost/timolol eye drops should not be used to initiate therapy.

United States - English - NLM (National Library of Medicine)

a-s medication solutions - latanoprost (unii: 6z5b6hvf6o) (latanoprost - unii:6z5b6hvf6o) - latanoprost ophthalmic solution is indicated for the reduction of elevated intraocular pressure (iop) in patients with open-angle glaucoma or ocular hypertension. known hypersensitivity to latanoprost, benzalkonium chloride, or any other ingredients in this product. risk summary there are no adequate and well-controlled studies of latanoprost ophthalmic solution administration in pregnant women to inform drug-associated risks. in animal reproduction studies, intravenous (iv) administration of latanoprost to pregnant rabbits and rats throughout the period of organogenesis produced malformations, embryofetal lethality and spontaneous abortion at clinically relevant doses [see data ]. the background risk of major birth defects and miscarriage for the indicated population is unknown. however, the background risk in the u.s. general population of major birth defects is 2 to 4%, and of miscarriage is 15 to 20% of clinically recognized pregnancies. data animal data embryofetal studies were conducted in pre

Canada - English - Health Canada

mantra pharma inc - latanoprost - solution - 50mcg - latanoprost 50mcg - prostaglandin analogs

Ireland - English - HPRA (Health Products Regulatory Authority)

actavis group ptc ehf - latanoprost, timolol maleate - eye drops solution - 50mcg/ml + 5 mg/ml - beta blocking agents

Ireland - English - HPRA (Health Products Regulatory Authority)

sanofi-aventis ireland limited t/a sanofi - latanoprost, timolol maleate - eye drops solution - 50mcg/ml + 5 mg/ml - beta blocking agents